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 CURRENTOPINION HDLs in crises
Arnold von Eckardstein and Lucia Rohrer
Purpose of review
The clinical utility of HDLs has been scrutinized upon the publication of Mendelian randomization studies
showing no effect of HDL-cholesterol (HDL-C) modifying variants on cardiovascular disease (CVD) outcome.
The failures of randomized controlled HDL-C-directed intervention trials have further fueled this skepticism.
This general criticism originates from oversimplification that has equated ‘HDL-C’ with ‘HDL’ and
misconceived both as the ‘good cholesterol’.
Recent findings
HDL particles are heterogeneous and carry hundreds of different lipids, proteins, and microRNAs. Many of
them but not cholesterol, that is, HDL-C, contributes to the multiple protective functions of HDLs that
probably evolved to manage potentially life-threatening crises. Inflammatory processes modify the
composition of HDL particles as well as their individual protein and lipid components, and, as a
consequence, also their functionality. Gain of dominant-negative functions makes dysfunctional HDL a part
rather than a solution of the endangering situation. Quantification of HDL particle numbers, distinct proteins
or lipids, and modifications thereof as well as bioassays of HDL functionality are currently explored toward
their diagnostic performance in risk prediction and monitoring of treatment response.
Summary
Any successful clinical exploitation of HDLs will depend on the identification of the most relevant
(dys)functions and their structural correlates. Stringent or prioritized structure-(dys)function relationships may
provide biomarkers for better risk assessment and monitoring of treatment response. The most relevant
agonists carried by either functional or dysfunctional HDLs as well as their cellular responders are
interesting targets for drug development.
Keywords
cholesterol efflux, dysfunctional HDL, innate host defense, reverse cholesterol transport,
sphingosine-1-phosphate bioassay
INTRODUCTION
Crises are ‘specific, unexpected, and nonroutine
events or series of events that [create] high levels
of uncertainty and threat or perceived threat to
an organization’s high priority goals.’ [1]. This
definition is fulfilled by the role and fate of HDLs
in both the life of an organism andmedical research
and development: HDLs help to prevent or manage
crises of the organism caused, for example, by
overload with cholesterol or xenobiotics, infectious
or sterile inflammation, or injury [2]. For several
decades, these properties as well as the association
of low HDL-cholesterol (HDL-C) with increased
cardiovascular risk [3,4] have generated consider-
able scientific interest in structure, function, metab-
olism, and regulation of HDL to exploit HDL for
treatment and prevention of cardiovascular diseases
(CVDs). Recent results of two lines of clinical or
epidemiological research, however, led to a general
critique of HDL’s causal role in the pathogenesis
of atherosclerotic CVD and hence suitability as a
therapeutic target. First, in randomized controlled
trials, HDL-C increasing drugs – namely fenofibrate,
nicotinic acid, and three inhibitors of cholesteryl
ester transfer protein (CETP) – did not reduce car-
diovascular event rates beyond statins [5]. Second,
in Mendelian randomization studies, several poly-
morphisms or rare mutants were found associated
with differences in HDL-C but not in cardiovascular
risk [6]. These criticisms overlook the nonlinear
relationship between HDL-C and cardiovascular risk
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which according to meta-analyses is significant
below the seventh decile only [3], the unsuitable
design of most intervention studies which did
not define HDL-C levels as inclusion/exclusion
criteria, and the pleiotropic effects of the investi-
gated drugs, which by alsomodulating plasma levels
of LDL-cholesterol (LDL-C) and/or triglycerides
do not allow any conclusion on the contribution
of HDL-C to trial failure [7]. Most importantly,
however, the cholesterol in HDL which is measured
by HDL-C is neither the mediator nor the reporter
of HDL function [2].
CRISIS PREVENTING AND SOLVING
PROPERTIES OF HDLs
HDLs are heterogeneous and multimolecular com-
plexes of hundreds of different molecules (proteins,
lipids, microRNAs, and additional amphiphilic or
lipophilic small molecules) [2]. Plasma concen-
trations of these molecules span four to five orders
of magnitude and range from submicromolar [lipid
transfer proteins, apoL1, sphingosine-1-phosphate
(S1P)] to millimolar (cholesterol, phosphatidyl-
choline) [2]. Assuming HDL particle concentration
of 20mmol/l, an average HDL particle carries 50–100
molecules of cholesterol or phosphatidylcholine
but less than 5% of the particles carry one molecule
of the minor constituents. Already these numbers
make clear that HDL-C cannot mirror the diversity
and functionality of HDLs.
HDLs protect the function and survival of the
organism by four different principle mechanisms.
Cholesterol efflux and reverse cholesterol
transport
As the classical function, HDLs mediate transport of
cholesterol from macrophage-foam cells to the liver
for biliary excretion. HDLs elicit cholesterol efflux
from cells via interaction with either ATP-binding
cassette (ABC) transporters or scavenger receptor B1
(SR-B1) [2,8]. ABCA1-mediated phospholipid and
cholesterol efflux was originally proposed to be
elicited by prebeta1-HDL, that is, lipid-free apoA-I.
The thereby generated discoidal nascent HDL
particles as well as spherical mature HDLs produced
by the subsequent esterification of cholesterol
through lecithin:cholesterol acyltransferase (LCAT),
were postulated to interact with SR-B1 and ABCG1
[2,8]. Recent systematic studies revealed that small
dense HDL particles and lipid-free apoA-I are the
most efficient mediators of cholesterol efflux [9
&
],
whereas ABCG1 did not contribute much to choles-
terol efflux to small HDLs and little to cholesterol
efflux to large HDLs. It rather appeared to mediate
transport of cholesterol from intracellular pools
to the plasma membrane [9
&
].
Reverse cholesterol transport (RCT) is of special
relevance for the removal of cholesterol frommacro-
phages [2,8,10
&
]. These cells of the innate immune
system can bypass the down-regulated LDL receptor
and take up modified lipoproteins through
scavenger receptors, cells, and their debris as well
as cholesterol crystals by different mechanisms of
engulfment (phagocytosis, efferocytosis, pinocyto-
sis) [10
&
]. Cholesterol-loadedmacrophage foam cells
exert several proinflammatory activities. Thus, cho-
lesterol loading of macrophages may have evolved
to support host defense to combat acute infections
and injuries [10
&
]. However, if not resolved, this
reaction propagates the pathogenesis of chronic
inflammatory diseases, including atherosclerosis
[10
&
]. Cholesterol efflux by HDLs was shown to
interfere with cytokine release. HDL-mediated cho-
lesterol efflux may hence have evolved to resolve
inflammation. In this regard, the opposite handling
of cholesterol by LDL and HDL in inflammation is
in analogy with the opposite action of different
products of lipoxygenases and cyclooxygenases in
inflammation, that is, lipoxins vs. leukotrienes and
resolvins vs. prostaglandins, respectively [11].
KEY POINTS
 HDLs exert multiple functions that contribute to host
defense from biological or chemical harm. These
functions are exerted by HDL-holoparticles as well as
specific agonists carried by HDL, for example, S1P.
These properties make HDL interesting therapeutic
targets even beyond prevention of CVDs.
 Inflammatory conditions modify both the composition
and the structural components of HDLs. The resulting
dysfunctional HDL particles not only lose protective
functions but also gain noxious properties.
 Neither physiological function nor pathological
dysfunction is recorded by the measurement of HDL-C.
Novel biomarkers are currently searched and validated
in clinical or epidemiological studies toward their
potential to aid in drug development and improve risk
prediction and monitoring of treatment response.
Candidate biomarkers include HDL particle numbers,
serum amyloid A, apoC-III, S1P, certain post-
translational modifications of apoA-I, and cholesterol
efflux capacity.
 The systematic elucidation of structure-function
relationships of functional and dysfunctional HDL, for
example, by a systems biology approach, may help
to discover novel biomarker candidates as well as
rationales and targets for therapeutic exploitation
of HDL.
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Cholesterol efflux and RCT are probably also
important means to compensate the dynamic and
dramatic changes of cholesterol content in adipo-
cytes elicited by the shrinkage of biomembranes
surrounding lipid droplets during lipolysis [12].
In cells with less extreme alterations of cholesterol
content, subtle HDL-induced changes in cellular
cholesterol homeostasis have been associated with
several changes of cellular differentiation and func-
tions [10
&
,13].
Signal transduction
HDLs elicit signal transduction processes which
regulate the differentiation and egress, proliferation,
survival, and function of various cell types [14]. In
the context of host defense, the convergence of
different HDL-induced cellular responses help to
limit the inflammatory action of myelocytes and
lymphocytes [11,15
&&
], provide integrity and func-
tionality of endothelial barriers [16], secure energy
homeostasis by stimulating insulin synthesis and
secretion by pancreatic beta cells as well as glucose
uptake by adipocytes and myocytes [17,18], stimu-
late angiogenesis [19], limit organ damage, and
facilitate wound healing [20].
The cellular responses happen as the result
of altered cholesterol homeostasis in specific plasma
membrane domains, or specific agonist-receptor
interactions activating signal transduction cascades.
In this regard, HDL/SR-BI and apoA-I/ABCA1-
interactions appear ambiguous. For example, the
interaction of HDLs with SR-B1 activates kinases
via its PDZ domain [14] or elicits cellular responses
by altering the cholesterol content of specific
plasma membrane domains that are enriched with
signaling molecules such as endothelial nitric oxide
synthase (eNOS) in caveolae of endothelial cells
[13]. Likewise, the interaction of apoA-I with ABCA1
has been proposed to elicit cellular responses such
as facilitated insulin secretion from beta cells or
inhibited cytokine secretion from macrophages
both indirectly by altering cellular cholesterol
homeostasis via cholesterol efflux and directly by
eliciting signal transduction, for example, through
recruitment of heterotrimeric G-protein GaS subu-
nits or induction of signal transducer and activator
of transcription 3 phosphorylation [14,17,18].
S1P is an example of less ambiguous agonist/
receptor interactions: S1P is enriched in about 5%
of plasma HDL particles by binding to apoM and
interacts with five different G-protein coupled S1P
receptors [14,21]. Apart from mediating the quan-
titative enrichment of S1P in HDLs, apoM does also
act as a chaperone thatmodulates the quality of S1P/
S1P receptor interactions. ApoM-bound and hence
HDL-carried S1P but not albumin-bound S1P
was found to inhibit the differentiation, prolifer-
ation, and egress of murine lymphocytes as well
as the suppression of NF-kB and intercellular
adhesion Molecule 1 (ICAM-1) in endothelial cells
[10
&
,17,22
&
]. In endothelial cells S1P promotes
nitric oxide production, junction closure, cell
proliferation and migration, as well as angiogenesis
and inhibits apoptosis as well as TNFa-induced
expression of vascular cell adhesion molecules
[12,21]. S1P also promotes the survival of cardio-
myocytes, hearts, and kidneys which are exposed
to hypoxia, ischemia-reperfusion injury, or toxic
drugs [14,21,23]. Some of these activities are also
exerted by S1P-free reconstituted HDLs. However,
the addition of S1P enhances the ability of S1P-free
reconstituted HDL to protect hearts from ischemia
reperfusion injury [23]. Moreover, HDLs were found
to stimulate S1P efflux from erythrocytes in both
apoM-dependent and apoM-independent manner.
Initially, S1P-free or S1P-poor HDLs may hence be
loaded with S1P during incubation with cells
[24,25
&
]. As the alternative to this mediation of
autocrine and paracrine effects, S1P-free and S1P-
containing HDLs may elicit identical cellular
responses by alternative mechanisms. Such mecha-
nistic redundancy, however, is another indication
for an important physiological role of HDLs.
Inactivation of extracellular biohazards
By its amphiphilic nature, HDLs can bind bacterial
lipopolysaccharides, oxidized lipids as well as xeno-
biotics [26]. In this respect, it is interesting to note
that HDLs have been isolated from several body
fluids that separate cells from their external environ-
ment, for example, tears, nasal fluid, saliva, and
bronchial fluid. [26] The intestine is even producing
HDLs by itself [27]. Potentially hazardousmolecules,
including cholesterol are either eliminated by
reverse transport to the liver or inactivated directly
on the surface of HDLs [26]. The best investigated
example for the latter situation is the hydrolysis of
oxidized phospholipids, which are transferred by
CETP or phospholipid transfer protein from LDLs
to HDLs [28], by paraoxonase 1 (PON1), lipoprotein
associated phospholipase A2, and lecithin:choles-
terol acyltransferase. Notably, the antiatherogenic
effect of PON1 is supported by data from clinical and
epidemiological observational studies as well as
genetic mouse models with knock-out or overex-
pression of PON1 [29].
Apart from inactivating or eliminating poten-
tially noxious agents, the amphiphilic structure
and specific molecules carried by HDLs also help
to counteract downstream adverse effects of
Lipid metabolism
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inflammation, for example, complement acti-
vation, coagulation, and platelet aggregation. Some
of these effects are exerted by apoA-I/phosphatidyl-
choline complexes, for example, the prevention
of von Willebrand factor’s self-association [30]
or complement activation by cholesterol crystals
[31]. Others are mediated by specific inactivators
or inhibitors carried by HDLs, for example, the
complement lysis inhibiting factor clusterin,
antiproteolytic serpins, or the anticoagulant protein
S [32,33].
Cellular uptake of HDLs or HDL components
HDLs deliver cargo to cells either by selective
uptake, that is, independently of the entire particle,
or via holoparticle uptake. Apart from mediating
selective uptake of lipids from HDLs into liver and
steroidogenic organs, SR-BI also facilitates the trans-
fer of other HDL-associated molecules to cells, for
example, microRNAs (miRNAs). In-vitro HDLs were
found to deliver miRNAs to hamster baby kidney
cells and human hepatocytes through SR-BI [34].
HDL-mediated delivery of miR-223 into endothelial
cells was found to suppress ICAM-1 [35]. However,
these findings are in contrast to those by Wagner
et al. [36] who confirmed the presence of low copy
numbers ofmiRNAs inHDLs, but found no evidence
that HDLs deliver functionally relevant amounts of
miRNAs into endothelial cells, smooth muscle cells,
or monocytes [36]. Wagner et al. [36] found 10000
copies of miR223 per mg HDL, that is, about 10pmol
HDL particles. The concentration of miR223 is
hence 7 to 8 orders ofmagnitude belowHDL particle
concentration. The delivery of sufficient numbers
of miRNA molecules for interference with several
RNA molecules will require the interactions of
a large number of HDL particles with a single cell.
If at all this will more likely happen by autocrine
or paracrine regulation of neighboring cells, that
is locally, by using HDLs as a shuttle of secreted
miRNAs as it has been described for exosomes [37],
rather than by endocrine regulation of distant
organs.
HDLs are also internalized by various cells,
including hepatocytes, monocyte-derived macro-
phages, enterocytes, and endothelial cells [38].
ApoA-I has been shown to stimulate the uptake of
HDL particles into hepatocytes and endothelial cells
by activating the ectopic F1-ATPase/P2Y receptor
axis [39]. In mice, the knock-out of P2Y13, which
activates hepatic HDL uptake, impaired RCT from
macrophage to feces and enhanced atherosclerosis
despite counter-balanced SR-BI upregulation [40
&
].
The potential clinical relevance of this F1-ATPase/
P2Ys axis in humans is indicated by the
identification of serum F1-ATPase inhibitor (IF1)
as an independent determinant of HDL-C and
coronary heart disease (CHD) risk [41].
In mice, the cubilin/megalin complex mediates
the uptake of HDL-like particles from the primary
urine into tubular epithelial cells of the kidney.
The knock-out of cubilin leads to decreased
plasma levels of HDL-C in mice suggesting that
this pathway may rescue some HDLs from renal
degradation [42]. Interestingly, the knock-out of
megalin or proteins regulating tubular endocytosis
as well as the knock-out of apoM, which is a ligand
of cubilin/megalin, led to the urinary excretion of
S1P [24].
Our and other labs provided evidence that
HDL-holoparticle uptake plays an important role
for transport of HDLs through endothelial barriers,
for example, into the vascular wall or into the brain
[43,44]. Cultured endothelial and epithelial cells
were observed to store HDLs or HDL components
within intracellular vesicles [43,45
&
] suggesting
that HDLs or its components also fulfil intracellular
functions. In fact, internalization of HDL is a
prerequisite for the killing of Trypanosoma brucei
by apoL1 [46]. Recently, internalization of HDLs
with concomitant recruitment of phosphorylated
IkB kinase into autophagosomes was suggested
as a means of preventing the TNFa-mediated
activation of NF-kB in the enterocyte cell line T84
and as a mechanism by which knock-out of apoA-I
and transgenic overexpression of human apoA-I
enhanced and suppressed, respectively, the intesti-
nal inflammation in a mouse model of inflamma-
tory bowel disease [45
&
].
PERSISTING CRISIS LEADS TO HDL
DYSFUNCTION
Very similar to the classical components of the
immune system, the functionality of HDLs appears
to be compromised by acute and chronic inflam-
matory conditions as well as metabolic decom-
pensation, including infections, rheumatic and
autoimmune diseases, CHD, diabetes, chronic
kidney disease, or familial hypercholesterolemia
[2,47]. The broad spectrum of HDL dysfunctions
include reduced capacities to stimulate cholesterol
efflux frommacrophages, to inhibit LDL oxidation,
apoptosis and, in endothelial cells, nitric oxide
production, monocyte chemoattractant protein 1
as well as VCAM expression [2,16,47]. The struc-
ture-function relationships of HDL dysfunction
(but also physiological function) are not compre-
hensively elaborated. Several dysfunctions have
been associated with different molecules within
HDLs. For example, endothelial HDL dysfunctions
HDL in crises von Eckardstein and Rohrer
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have been assigned to the loss of S1P, plasmalo-
gens, or clusterin, enrichment with serum amyloid
A (SAA), apoC-III, or symmetric dimethylarginine,
as well as oxidative modifications of apoA-I or
phospholipids [2,16,25
&
,47–50,51
&
]. Differences
in cholesterol efflux capacity (CEC) have been
attributed to alterations in HDL particle number,
HDL subclass distribution, the kinetics of HDL/
apoA-I exchange, in phospholipid composition,
the accumulation of SAA, or post-translational
modifications of apoA-I [2,47,52–59,60
&
]. As yet,
villains and bystanders are not unequivocally
discriminated.
In bioassays, most dysfunctions are recorded as
reduction of normal functionality [2,47]. Beyond
this apparent loss of function, HDLs of patients
with CHD or chronic kidney disease were found
to inhibit rather than stimulate nitric oxide
production because they gained the ability to
interact with the lectin-like oxidized LDL receptor
LOX-1 and the Toll-like receptors TLR2 and TLR4,
respectively, and thereby induced the phosphoryl-
ation of inhibitory rather than activating sites
in eNOS [49,50]. Also SAA enrichment was found
to generate noxious HDLs which in endothelial
cells inhibit nitric oxide production and stimulate
the production of reactive oxygen species as well
as the expression of vascular cell adhesion
molecule 1 [51
&
]. These findings raise the question
whether also apparent loss-of-functions are caused
by dominant negative effects. For example, the
myeloperoxidase-mediated oxidation of Tyr-192
or Trp-72 residues in apoA-I which has been
related to decreased CEC, affects about 20% of
apoA-I in atherosclerotic plaques but only 0.02%
of apoA-I molecles in plasma of CHD patients
[56,57]. By loss of function, these modifications
may limit macrophage cholesterol efflux locally
within the arterial wall and contribute to the
pathogenesis of atherosclerosis. However, the
quantitatively very minor alterations can only
markedly reduce CEC of total or apoB-free plasma,
if they inhibit the cellular cholesterol efflux
machinery. Interestingly, the injection of myelo-
peroxidase-oxidized apoA-I into mice decreased
HDL-C levels and RCT from macrophages into
plasma, whereas injection of nonoxidized apoA-I
increased both HDL-C and RCT [58]. Likewise, the
injection of HDLs of CKD patients increased blood
pressure in mice [50]. The decreased CEC of HDLs
enriched with SAA was explained by enhanced
affinity to proteoglycans which prevents the
access of HDLs to the plasma membrane [60
&
].
These examples are the first indications that gain
of dysfunction converts originally protective HDLs
into noxious particles.
CRITICAL FINDINGS IN EPIDEMIOLOGICAL
AND CLINICAL RESEARCH
By contrast to previous studies [3,4], several recent
studies did not find the inverse association between
HDL-C and CHD events in patients with chronic
or acute CHD [60
&
,61,62]. Also a systematic com-
parison of associations between lipid risk factors and
CHD events in three US-American population
studies found the association of HDL-C (but also
other lipid risk factors) with incident CHD weak-
ened in the contemporary studies with baseline
levels assessed between 2003 and 2007 as compared
with the older atherosclerosis risk in communities
(ARIC) study (with baseline levels assessed between
1988 and 1997) [63
&
]. The authors made the more
prevalent statin use responsible for this secular
trend. An alternative or additional explanation
may be the changes in the methodology of HDL-C
determination: the nowadays used homogenous
assays for the determination of HDL-C (but also
LDL-cholesterol) are notoriously inaccurate especi-
ally in dyslipidemic samples [64,65].
The negative results of randomized outcome
trials on the add-on statin therapies with fenofi-
brate, niacin, or CETP inhibitors are frequently used
arguments against the causal role and hence
therapeutic suitability of HDLs [6]. However, in
the randomized trials the effects of niacin or fenofi-
brate on HDL-C levels were rather modest (<10%).
Moreover, with the exception of dalcetrapib [59],
all drugs also beneficially affect LDL-C and
lipoprotein(a) (niacin, torcetrapib, evacetrapib)
and triglycerides (niacin and fenofibrate) [7]. These
intervention trials hence do not allow any con-
clusion on the causal contribution of HDL-C to their
failure. According to a recent meta-analyses, fibrates
and niacin prevented cardiovascular events in the
absence of statins but not if combined with statins
[6]. Post hoc analyses revealed that patients with low
HDL-C (<35mg/dl/<0.9mmol/l) and hypertrigly-
ceridemia (>200mg/dl/>2.3mmol/l) benefit from
treatment with fibrates independently of whether or
not they were combined with statins [66]. Genetic
post hoc analyses of the dal-OUTCOME study ident-
ified genetic differences in the adenylate cyclase
9 locus (ADCY9) as discriminators of dalcetrapib’s
efficacy [67
&
]. Dalcetrapib treatment decreased the
cardiovascular event rate by 39% in patients with
the AA genotype at rs1967309 of the ADCY9 locus
but increased cardiovascular event rates by 27% in
patients with the GG genotype [67
&
]. Randomized
trials in such preselected patient groups are
needed to prove that personalized treatment of
patients with the low HDL-C/hypertriglyceridemia
syndrome with fibrates or with the AA genotype
at rs1967309 with a CETP inhibitor is effective.
Lipid metabolism
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Mendelian randomization studies provided
evidence that associations with CHD risk of LDL-C,
lipoprotein(a), and triglycerides but not withHDL-C
are causal. Genetic mutants or polymorphisms that
are associated with differences in HDL-C were
not found associated with any differences in the
prevalence or incidence of CHD events [5]. CETP
polymorphisms are an exception in this regard.
Carriers of CETP alleles associated with low CETP
activity and, as the consequence, higher levels of
HDL-C as well as lower levels of LDL-C and trigly-
cerides have reduced risk of CVD [68,69]. It has been
argued that these associations are driven by the
effects of the polymorphisms on triglycerides and
LDL-C [68]. However, it is important to recall that
these polymorphisms like pharmacological CETP
inhibitors primarily affect CETP activity and only
secondarily lipid traits. The failures of torcetrapib,
dalcetrapib [6,62], and possibly also evacetrapib [70]
to reduce CHD event rates indicate that inborn and
acquired decreases in CETP activity may have a
different impact on CHD. This example points
to limitations of the genetic strategy to predict
outcome of pharmacological intervention.
Observational studies also found inverse associ-
ations between HDL-C and risks of ischemic stroke
[3,71], progression of aortic aneurysm [72], inci-
dence of diabetes mellitus [17,73,74], breast cancer
[75] and colorectal cancer [76], as well as fatality of
sepsis [77]. Although statistically independent of
potential confounders, these associations also raise
questions on causality. Two Mendelian randomiz-
ation studies came to opposite conclusions on the
causal association of low HDL-C with increased risk
of diabetes mellitus: In the Copenhagen City Heart
Study HDL-C levels but not genetic polymorphisms
that influence HDL-C were found associated with
incident diabetes mellitus [73]. By contrast, a meta-
analysis of 140 single nucleotide polymorphisms
known to affect plasma lipids found both measured
and genetically determined elevations of HDL-C
levels were found associated with decreased risk of
diabetes mellitus [74]. Age-related macular degener-
ation provides an opposite example, where risk
increases with increasing HDL-C [78]. The 442Gly
encoding allele of the CETP gene which increases
HDL-C and decreases CHD risk was found associated
with elevated risk of age-related macular degener-
ation in an East Asian population [79].
STRATEGIES TO COPE WITH THE
CRITICAL CLINICAL UTILITY OF HDLs
As HDL-C is no longer accepted as a surrogate
marker for drug development, biomarkers that
reflect HDL function are searched. Such biomarkers
must not only show diagnostic or prognostic supe-
riority over HDL-C as well as modifiable risk associ-
ation but they must also be technically feasible in
terms of preanalytical requirements, accessibility,
and turnaround time as well as analytically well
controlled in terms of precision, accuracy, and trace-
ability [80,81]. As yet most criteria are either not
fulfilled or not proven by novel HDL biomarkers.
HDL particles and subclasses
Particle numbers and size subclasses of HDLs can
be determined by NMR spectroscopy and ion mobi-
lity. Nondenaturing gradient gel electrophoresis
and agarose gel electrophoresis differentiate HDL
subclasses by size and charge, respectively. The sub-
classes as determined by the different technologies
cannot be simply interconverted but a consensus
was reached that distinguishes five HDL subclasses
by size [82]. By contrast to HDL subclasses, HDL
particle numbers (HDL-P) as determined by NMR
showed rather consistent inverse associations with
risk of CHD events [83]. However, only some studies
showed superiority of HDL-P over HDL-C (multiple
risk factor intervention trial, multi-ethnic study
of atherosclerosis (MESA), Dallas Heart Study,
the Rosuvastatin arm of JUPITER) [84–87], whereas
others did not (Women’s Health study, community-
based cohort study (CMCS) Beijing project, EPIC
Norfolk, and the placebo arm of JUPITER)
[87–90]. Interestingly, the CMCS Beijing project
found the HDL-C/HDL-P ratio positively associated
with the progression of carotid atherosclerosis [89].
This observation was also made in MESA and may
indicate dysfunction of cholesterol-overloaded HDL
particles or impairment in RCT. This is also indi-
cated by the association of cholesterol-enriched
particles with increased risk of CHD and reduced
CEC in patients with high HDL-C levels [55].
Although MESA proved superiority of HDL-P, the
use of HDL-P together with LDL-P did not improve
overall risk prediction by the AmericanHeart Associ-
ation/American College of Cardiology calculator
score [91]. Also of note, in the JUPITER study,
HDL-P as determined byNMR but not as determined
by ion mobility was associated with incident CHD
[92]. Finally, it is important to note that most pub-
lished data from outcome studies were obtained by
theNMRmethod developed by LipoSciencewhich is
now commercialized as LipoProfile. At least three
alternative NMR-based methods for HDL-P determi-
nations use different algorithms for the analysis
of NMR signals [93–95]. Two of them are also
commercialized (LipoScale and LipoFit) [93,94].
LipoProfile and LipoScale yield HDL-P concen-
trations that show mean deviations of more than
HDL in crises von Eckardstein and Rohrer
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60% from each other as well as discrepant corre-
lations with HDL-apoA-I levels [93]. Systematic
method comparisons and large observational stud-
ies are needed for all methods to harmonize HDL-P
determination and to prove the diagnostic value of
HDL-P independently of the method used.
Bioassays of HDL function
CEC, HDL-induced nitric oxide and superoxide
production in endothelial cells as well as serum
PON-1 activity show good precision within special-
ized labs [95,96,97
&
,98] but accuracy and agreement
of measurements between labs are unknown
because of lacking reference material and absence
of systematic external quality assessment surveys.
Efflux of radiolabeled cholesterol and efflux of a
fluorescent cholesterol analogue from J774 cells
showed rather poor agreement with a coefficient
of correlation of 0.52 [97
&
]. Nevertheless, upon
either method low CEC from J774 cells predicted
cardiovascular events in three prospective cohort
studies [97
&
,99
&
,100
&
]. By contrast, CEC as
determined by the use of RAW cells or THP1 cells
as the cholesterol donors did not show the inverse
association with cardiovascular events during the
follow-up of patients who underwent diagnostic
coronary angiography and kidney transplantation,
respectively [101,102
&
]. Rather by contrast, CEC
determined in the presence of RAW cells was posi-
tively associated with the incidence of cardiovascu-
lar events, although it showed very good agreement
with CEC determined from J774 cells (r¼0.92)
[101]. In the kidney-transplanted patients, CEC
from THP1 cells was independently associated with
graft survival but not with cardiovascular events or
mortality [102
&
]. The increase in CEC but lack of
clinical efficacy upon treatment with dalcetrapib or
evacetrapib [103,104] indirectly question the utility
of CEC to aid in drug development or monitoring
of treatment success. Laborious and artifact-prone
ultracentrifugation [105] limits the feasibility of
bioassays such as recording of endothelial and
anti-inflammatory functionalities in large sample
numbers of clinical or epidemiological studies.
Nevertheless, systematic head to head comparisons
are needed to establish the HDL functionality
which has the strongest association with CHD
and treatment response and is, therefore, likelymost
relevant for the antiatherogenicity of HDLs.
HDL components
Apart from HDL-C, apoA-I has been most exten-
sively investigated for its association with incident
CHD. Overall apoA-I and HDL-C appear to have
similar prognostic values [3,4]. Meta-analyses of
statin trials revealed that on-treatment changes
of apoA-I levels but not on-treatment changes of
HDL-C are associated with outcome. However,
the association is too weak for clinical utility [4].
Structure-function relationships of HDLs’ func-
tion and dysfunction are not comprehensively
elaborated. Most of them have been detected
by explorative parallel functional, proteomic, lipi-
domic, or transcriptomic characterization of HDLs
in relatively small case-control studies [25
&
,48–
50,51
&
,56,57]. Only a few of them have been
validated in larger longitudinal studies. The signifi-
cant inverse association between PON1 activity and
CHD was shown in several studies. It appears to be
stronger in diabetic patients than in nondiabetic
subjects [29]. In the Physician’s Health and Nurses
Health Studies, cholesterol in apoC-III-containing
HDLs showed a positive association with incident
CHD, whereas cholesterol in apoC-III-free HDLs
showed the expected inverse association [106]. In
diabetic patients on hemodialysis, a high SAA con-
tent of HDLs was associated with increased risk of
cardiovascular events and death [107]. Interestingly,
in the same study, cohort levels of apoA-II but not
apoA-I or HDL-C were predictors of cardiovascular
morbidity and total mortality [108]. In the LURIC
study of 3310 patients undergoing coronary angiog-
raphy, plasma levels of SAA and HDL-C were found
to interact: in patients with plasma SAA levels below
the 80th percentile, HDL-C showed the expected
inverse association with all-cause and cardiovascu-
lar mortality. In patients with elevated SAA levels,
the opposite associations were found [51
&
]. Based on
these findings, the authors derived a formula to
calculate ‘biologically effective HDL-C’. In two rep-
lication studies, one on the hemodialysis patients
mentioned before and the other in the population-
based cooperative health research in the region of
Augsburg cohort, ‘biologically effective HDL-C’ but
not measured HDL-C predicted outcome [51
&
].
CONCLUSION
By their many functions in innate host defense,
HDLs remain interesting targets for the clinical
management of diseases, even beyond CVD.
However, any successful clinical exploitation will
depend on the identification of the most relevant
(dys)functions and their structural correlates. This
needs a study that comprehensively characterizes
HDLs of healthy and diseased donors for structure
(particle size by NMR and particle composition by
proteomics, lipidomics, miRNA transcriptomics)
and function (diverse bioassays, e.g., on CEC from
macrophages and eNOS activation in endothelial
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cells). Combinedwith bioinformatics such a systems
biological approach may prioritize (dys)functions
and components which aremost strongly correlated
with each other and most closely associated
with disease states. The most stringent structure-
(dys)function-phenotype relationships will provide
biomarker candidates to improve risk assessment
and monitoring of treatment response. The most
relevant agonists of either functional or dysfunc-
tional HDLs are interesting targets for drug develop-
ment, either directly themselves or indirectly
by unravelling their downstream cellular responders
as therapeutic targets. Mediators of physiological
protective functions would need activation,
whereas mediators of HDL dysfunction would need
inhibition. Lost functional HDL components would
need replenishment, for example, by HDL mimetics
[109] or activation. Mediators of dominant negative
dysfunctions must be either eliminated or inhibited
in formation or action. Any therapy that prolongs
the residence time of HDLs with gained dysfunction
will be rather harmful, even if it increases
HDL-C levels.
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